Cochrane · systematic review · CD007585
Lymphadenectomy for the management of endometrial cancer
Frost, JA, Webster, KE, Bryant, A, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 80%High 1 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings table
Population: women with stage I endometrial cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 1.07 [0.81, 1.43] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Recurrence‐free survival | HR 1.23 [0.96, 1.58] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Direct surgical morbidity | RR 1.93 [0.79, 4.71] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Surgery‐related systemic morbidity | RR 3.72 [1.04, 13.27] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Lymphoedema or lymphocyst | RR 8.39 [4.06, 17.33] | 2 studies · 1922 participants | High |
Summary of findings table
Population: women with stage I endometrial cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 1.07 [0.81, 1.43] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Recurrence‐free survival | HR 1.23 [0.96, 1.58] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Direct surgical morbidity | RR 1.93 [0.79, 4.71] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Surgery‐related systemic morbidity | RR 3.72 [1.04, 13.27] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Lymphoedema or lymphocyst | RR 8.39 [4.06, 17.33] | 2 studies · 1922 participants | High |
SoF table
Population: patients with Endometrial cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 1.07 [0.81, 1.43] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Recurrence‐free survival | HR 1.23 [0.96, 1.58] | 2 studies · 1851 participants | Moderate Downgraded: imprecision |
Direct surgical morbidity | RR 1.93 [0.79, 4.71] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Surgically related systemic morbidity | RR 3.72 [1.04, 13.27] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |
Lymphoedema or lymphocyst | RR 8.39 [4.06, 17.33] | 2 studies · 1922 participants | Moderate Downgraded: imprecision |